	US 12,110,521 B2
	Engineered methionine gamma lyase variants
Kierra Aleece Franklin, Dolton, IL (US); Stephanie Sue Galanie, Knoxville, TN (US); Gjalt W. Huisman, Redwood City, CA (US); Nikki D. Kruse, San Carlos, CA (US); Kerryn McCluskie, Pacifica, CA (US); Vesna Mitchell, Santa Clara, CA (US); Leann Quertinmont Teadt, Redwood City, CA (US); and Kristen Jean Vallieu, Las Vegas, NV (US)
Assigned to SYNTIS BIO, INC., Boston, MA (US)
Filed by Syntis Bio, Inc., Boston, MA (US)
Filed on May 19, 2022, as Appl. No. 17/749,034.
Claims priority of provisional application 63/274,349, filed on Nov. 1, 2021.
Claims priority of provisional application 63/191,799, filed on May 21, 2021.
Prior Publication US 2022/0403362 A1, Dec. 22, 2022
Int. Cl. C12N 9/88 (2006.01); A61K 38/51 (2006.01); A61P 3/00 (2006.01); C12N 1/20 (2006.01); C12N 15/70 (2006.01); C12R 1/19 (2006.01)

CPC C12N 9/88 (2013.01) [A61K 38/51 (2013.01); A61P 3/00 (2018.01); C12N 1/205 (2021.05); C12N 15/70 (2013.01); C12Y 404/01011 (2013.01); C12N 2800/101 (2013.01); C12R 2001/19 (2021.05)]

24 Claims

1. A recombinant methionine gamma lyase comprising a polypeptide sequence comprising at least 85% sequence identity to the reference sequence of SEQ ID NO: 1488, wherein the polypeptide sequence comprises at least a substitution 189I/L/M/P/S, 69I/R/W, 237K/A/G/H/L/R/T/Y, 236A/C/R, or 341F, or combinations thereof, wherein the amino acid positions are relative to the reference sequence of SEQ ID NO: 2.